Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 13 May 2022 Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab Read More 10 May 2022 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis Read More 2 May 2022 JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) Read More 28 Apr 2022 UCB’s General Meeting of Shareholders 2022 Read More 22 Apr 2022 Disposal of own shares Read More 15 Apr 2022 Disposal of own shares Read More Pagination First page Previous page Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
